The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...
Breo Ellipta, a dual-therapy inhaler combining an ICS and LABA, was similarly found to provide comparable or incremental net ...
U.K.-based GlaxoSmithKline is launching Trelegy with a list price of $530 per month ... The Incruse and Breo inhalers, both launched since 2014, and the Anoro inhaler launched in 2013 have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results